MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial - Takeaways - MDSpire

MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial

  • By

  • Martin Wermke

  • Sebastian Ochsenreither

  • Dirk Jaeger

  • Heiko Becker

  • Annalen Bleckmann

  • Farastuk Bozorgmehr

  • Manik Chatterjee

  • Stefanie Groepper

  • Mathias Haenel

  • Judith S. Hecker

  • Max-Felix Häring

  • Daniel Heudobler

  • Norbert Hilf

  • Martin Hofmann

  • Meike Hutt

  • Andrea Mayer-Mokler

  • Sarah Missel

  • Manuel Ruh

  • Heiko Schuster

  • Olga Veremchuk

  • Moritz Kleemiss

  • Stefan Knop

  • Simon Laban

  • Martin Sebastian

  • Silvia Spoerl

  • Cedrik Michael Britten

  • Carsten Reinhardt

  • May 31, 2026

Share

  • 1

    IMA401 is a TCR-based bispecific T cell engager targeting MAGE-A4 and MAGE-A8 in patients with recurrent or refractory solid tumors.

  • 2

    The study evaluates IMA401's safety, tolerability, pharmacokinetics, and initial antitumor activity as monotherapy and with pembrolizumab.

  • 3

    MAGE-A4/8 target peptide shows high presentation levels on tumor cells and is nearly absent in normal tissues, providing a favorable therapeutic window.

  • 4

    IMA401 combines a high-affinity TCR-based domain with a low-affinity T-cell-recruiting domain for enhanced T cell activation and tumor targeting.

  • 5

    The primary objective of the IMA401-101 study is to determine the maximum tolerated dose and/or recommended phase 2 dose of IMA401.

Original Source(s)

MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial

  • by Martin Wermke, Sebastian Ochsenreither, Dirk Jaeger, Heiko Becker, Annalen Bleckmann, Farastuk Bozorgmehr, Manik Chatterjee, Stefanie Groepper, Mathias Haenel, Judith S. Hecker, Max-Felix Häring, Daniel Heudobler, Norbert Hilf, Martin Hofmann, Meike Hutt, Andrea Mayer-Mokler, Sarah Missel, Manuel Ruh, Heiko Schuster, Olga Veremchuk, Moritz Kleemiss, Stefan Knop, Simon Laban, Martin Sebastian, Silvia Spoerl, Cedrik Michael Britten, Carsten Reinhardt

  • May 31, 2026

Related Content

Outcomes of critically ill pediatric patients after haploidentical stem cell transplantation

Real-world healthcare resource use and costs associated with the management of locally advanced head and neck cancer in Portugal – TRACE2 study

Stimuli-responsive nanoplatforms for sonodynamic immunotherapy: opportunities and challenges in cancer treatment